Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriasis Vulgaris
Interventions: CT327 0.05%, CT327 0.1%, CT327 0.5%, Placebo; Drug
Lead sponsor: Creabilis SA; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Hotsprings, Arkansas • San Ramon, California • Bay City, Michigan + 5 more

Conditions: Psoriasis
Interventions: Artificial intelligence, Human, Standard of Care; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Psoriatic Arthritis
Interventions: Treatment with Apremilast; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Psoriasis
Interventions: Calcipotriene 0.005% Foam; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: San Diego, California • Ormond Beach, Florida • Tampa, Florida + 6 more

Conditions: Psoriasis
Interventions: Desoximetasone Spray 0.25%, placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hazleton, Pennsylvania

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: Psoriasis
Interventions: Calcitriol ointment, Clobetasol spray; Drug
Lead sponsor: Emer, Jason, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions: Breast milk sampling, Certolizumab Pegol; Procedure · Biological
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Plaque Psoriasis
Interventions: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen, Clobex® Spray morning and Vectical™ Ointment evening regimen; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Evansville, Indiana + 2 more

Conditions: Psoriasis
Interventions: Brodalumab; Biological
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: San Diego, California • Miami, Florida • Henderson, Nevada + 1 more

Conditions: Scalp Psoriasis
Interventions: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel); Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: San Diego, California • Jacksonville, Florida • Ormond Beach, Florida + 3 more

Conditions: Psoriasis
Interventions: AbGn168 intravenous infusion, AbGn168 subcutaneous injection; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 6
States / cities: Boise, Idaho • Evansville, Indiana • Baltimore, Maryland + 3 more

Conditions: Psoriasis
Interventions: VTP-43742, Placebo 1, Placebo 2; Drug
Lead sponsor: Vitae Pharmaceuticals Inc., an Allergan affiliate; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Rogers, Arkansas • Miami, Florida • Tampa, Florida + 9 more

Conditions: Psoriasis
Interventions: MEDI-507; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001
U.S. locations: 3
States / cities: Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington

Conditions: Psoriatic Arthritis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Boise, Idaho • Lexington, Kentucky • Baton Rouge, Louisiana + 17 more

Conditions: Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions: Herpes Zoster (HZ) Vaccine, Placebo; Biological · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more

Conditions: Psoriatic Arthritis
Interventions: Ultrasound; Device
Lead sponsor: Ottawa Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Plaque Psoriasis
Interventions: LCD Solution with NB-UVB Phototherapy, NB-UVB Light Device (311-315 nm); Other · Device
Lead sponsor: NeoStrata Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Plaque Psoriasis
Interventions: IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 18
States / cities: Encino, California • San Diego, California • Santa Rosa, California + 15 more

Conditions: Arthritis, Psoriatic
Interventions: Apremilast (CC-10004), Apremilast (CC-10004) Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 54
States / cities: Mesa, Arizona • Covina, California • Encino, California + 48 more

Conditions: Arthritis, Psoriatic
Interventions: Onercept, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 37
States / cities: Little Rock, Arkansas • Fresno, California • Irvine, California + 28 more

Conditions: Plaque Psoriasis
Interventions: Calcipotriene/betamethasone; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Psoriatic Arthritis
Interventions: AMG 827 140, Placebo, AMG 827 280, AMG 827 210; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 22
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more

Search by objective public record fields.

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Assessing Psoriasis Treatment Outcomes

Treatment With Apremilast in Patients With Psoriatic Arthritis

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

Psoriatic Arthritis Study of Izokibep

Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Validation of Handheld Ultrasound Devices in Rheumatology

NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

AMG 827 in Subjects With Psoriatic Arthritis